A drug used under the brand names Onureg to treat adults with certain types of acute myeloid leukemia and Vidaza to treat adults with certain types of myelodysplastic syndromes and children aged 1 month and older with newly diagnosed juvenile myelomonocytic leukemia. It is also being studied in the treatment of other types of cancer. Azacitidine stops cells from making DNA and may kill cancer cells. It is a type of antimetabolite. US Brand Name(s): Onureg, Vidaza. FDA Approved: Yes
Are you looking for or in search of FDA approved “sacituzumab govitecan-hziy for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of sacituzumab govitecan-hziy injection, get in touch with our healthcare professional.
Azacitidine is indicated for the treatment of myelodysplastic syndrome, for which it received approval by the U.S. Food and Drug Administration (FDA) on May 19, 2004. In two randomized controlled trials comparing azacitidine to supportive treatment, 16% of subjects with myelodysplastic syndrome who were randomized to receive azacitidine had a complete or partial normalization of blood cell counts and bone marrow morphology, compared to none who received supportive care, and about two-thirds of patients who required blood transfusions no longer needed them after receiving azacitidine. Azacitidine is also indicated for the treatment of myeloid leukemia and juvenile myelomonocytic leukemia.
Azacitidine is approved to treat:
Acute myeloid leukemia in adults who had a first complete remission after intensive induction therapy and who are not able to finish intensive curative therapy. This use is approved for the Onureg brand of azacitidine.
Myelodysplastic syndromes (MDS).